Lineage Cell Therapeutics (LCTX) Free Cash Flow Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 96.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -39.33% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 31.57% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 152.82% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 58.53% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -32.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.13% |
| Mar 31, 2026 | -63.21% |
| Dec 31, 2025 | 22.10% |
| Sep 30, 2025 | 38.18% |
| Jun 30, 2025 | -6.26% |
| Mar 31, 2025 | 14.40% |
| Dec 31, 2024 | -12.93% |
| Sep 30, 2024 | -10.32% |
| Jun 30, 2024 | 20.32% |
| Mar 31, 2024 | 48.92% |
| Dec 31, 2023 | 22.68% |
| Sep 30, 2023 | 10.23% |
| Jun 30, 2023 | 8.38% |
| Mar 31, 2023 | -152.13% |
| Dec 31, 2022 | -31.28% |
| Sep 30, 2022 | -17.63% |
| Jun 30, 2022 | -29.11% |
| Mar 31, 2022 | 393.99% |
| Dec 31, 2021 | -6.25% |
| Sep 30, 2021 | -0.64% |